NCT03546686: Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women with Triple-negative Breast Cancer |
|
|
| Recruiting | 2 | 80 | US | Pembrolizumab, Core Biopsy/Cryoablation, Breast Surgery, Ipilimumab, Nivolumab | University of Texas Southwestern Medical Center, Susan G. Komen Breast Cancer Foundation, Bristol-Myers Squibb, Boston Scientific Corporation, American Society of Clinical Oncology | Breast Cancer | 06/26 | 06/28 | | |
